HPV Vaccines
The HPV vaccines like Gardasil, Gardasil 9, and Cervarix were approved by the FDA. These vaccines prevent infections with HPV types 16 and 18. The HPV types 6 and 11 are prevented by the vaccine Gardasil. The phenomenon is called cross-protection in which the vaccines are found to provide some protection against a few additional HPV types.
Related Conference of HPV Vaccines
April 22-23, 2025
8th International Conference on Vaccines, Immunology and Clinical Trials
Paris, France
HPV Vaccines Conference Speakers
Recommended Sessions
- Allergy & Asthma Vaccines
- Antibodies Research
- Chicken Pox Vaccines
- Clinical Immunology & Immunopathology
- Flu Vaccines
- HIV Vaccines
- HPV Vaccines
- Immune System Disorders
- Immunization Challenges
- Immunology
- Infectious and Non-infectious diseases Vaccines
- Onco-Immunology
- Paediatric Vaccines
- Pediatric Immunology
- Plant Vaccines & Veterinary Vaccines
- Recombinant Vaccines
- Stem Cell Immunology
- Therapeutic Cancer Vaccines
- Transplant Immunology
- Travel & Edible Vaccinations
- Vaccine Types
- Vaccine-Induced Immunity
- Vaccines
- Vaccines and Immunology Advancements
- Vaccines Efficacy and Safety
- Zika Virus Vaccines
Related Journals
Are you interested in
- Advancements in Vaccine Adjuvants - Vaccines R&D 2025 (France)
- Advances in Vaccine Safety Monitoring - Vaccines R&D 2025 (France)
- Antimicrobial Resistance (AMR) - VACCINES WORLD 2025 (Italy)
- Bioprocessing and Manufacturing - VACCINES WORLD 2025 (Italy)
- Biosecurity and Bioterrorism Preparedness - GLOBAL VACCINE 2025 (Indonesia)
- Cancer Vaccines and Immunotherapy - VACCINES WORLD 2025 (Italy)
- Cancer Vaccines and Immunotherapy - GLOBAL VACCINE 2025 (Indonesia)
- Cancer Vaccines and Immunotherapy - Euro Vaccines 2025 (France)
- Childhood Vaccines and Maternal Vaccines - Euro Vaccines 2025 (France)
- Clinical Trials - VACCINES WORLD 2025 (Italy)
- Clinical Trials and Regulatory Affairs - GLOBAL VACCINE 2025 (Indonesia)
- Clinical Trials and Vaccine Research - Vaccines R&D 2025 (France)
- Community Engagement and Public Health Campaigns - Vaccines R&D 2025 (France)
- Conjugate Vaccine - VACCINES WORLD 2025 (Italy)
- Conjugate Vaccine - GLOBAL VACCINE 2025 (Indonesia)
- Coronavirus (COVID-19) & Pandemic Vaccines - VACCINES WORLD 2025 (Italy)
- DNA Vaccines - Euro Vaccines 2025 (France)
- DNA-RNA Vaccines - VACCINES WORLD 2025 (Italy)
- Emerging and Re-Emerging Diseases - VACCINES WORLD 2025 (Italy)
- Emerging Technologies in Diagnostics - GLOBAL VACCINE 2025 (Indonesia)
- Epidemiology and Public Health - GLOBAL VACCINE 2025 (Indonesia)
- Ethics and Public Policy in Vaccination - Vaccines R&D 2025 (France)
- Fungal/Bacterial/Viral/Parasitic/STD Vaccines - VACCINES WORLD 2025 (Italy)
- Global Vaccine Distribution Challenges - Vaccines R&D 2025 (France)
- Hepatitis Vaccines - Euro Vaccines 2025 (France)
- HIV Vaccines - VACCINES WORLD 2025 (Italy)
- HIV Vaccines - GLOBAL VACCINE 2025 (Indonesia)
- HIV/AIDS Vaccines - Euro Vaccines 2025 (France)
- Human Preventive & Therapeutic Vaccines - Euro Vaccines 2025 (France)
- Human Vaccines - Infectious & Non Infectious Diseases - Euro Vaccines 2025 (France)
- Immune Profiling - VACCINES WORLD 2025 (Italy)
- Immunization Programs and Strategies - GLOBAL VACCINE 2025 (Indonesia)
- Immunology Advances and Vaccine Efficacy - Vaccines R&D 2025 (France)
- Immunology/Animal Models - Euro Vaccines 2025 (France)
- Impact of Climate Change on Infectious Disease and Vaccination - Vaccines R&D 2025 (France)
- Infectious and Non-Infectious Diseases - VACCINES WORLD 2025 (Italy)
- Influenza and Respiratory Vaccines - VACCINES WORLD 2025 (Italy)
- Innovations in Vaccine Formulation and Delivery - Vaccines R&D 2025 (France)
- Innovative Vaccine Development - GLOBAL VACCINE 2025 (Indonesia)
- Innovative Vaccine Technologies - Vaccines R&D 2025 (France)
- Integration of Digital Health in Immunization - Vaccines R&D 2025 (France)
- Mucosal Vaccines - Euro Vaccines 2025 (France)
- Nanotechnology in vaccines - GLOBAL VACCINE 2025 (Indonesia)
- Next-Generation Vaccine Delivery Technologies - Euro Vaccines 2025 (France)
- Next-Generation Vaccine Delivery Technologies - GLOBAL VACCINE 2025 (Indonesia)
- Pandemic Preparedness and Response - GLOBAL VACCINE 2025 (Indonesia)
- Personalized Immunization Strategies - Vaccines R&D 2025 (France)
- Rapid Vaccine Development and Deployment - Vaccines R&D 2025 (France)
- Technological Innovations in Vaccinology - GLOBAL VACCINE 2025 (Indonesia)
- Thermo Stabilized Vaccines - VACCINES WORLD 2025 (Italy)
- Thermo-stabilized vaccines - GLOBAL VACCINE 2025 (Indonesia)
- Vaccination in Special Populations - Vaccines R&D 2025 (France)
- Vaccine Access and Equity - GLOBAL VACCINE 2025 (Indonesia)
- Vaccine Adjuvants - Euro Vaccines 2025 (France)
- Vaccine Adjuvants - VACCINES WORLD 2025 (Italy)
- Vaccine Adjuvants - GLOBAL VACCINE 2025 (Indonesia)
- Vaccine Innovation for Emerging Diseases - Vaccines R&D 2025 (France)
- Vaccine Production, Supply & Logistics - VACCINES WORLD 2025 (Italy)
- Vaccine Research & Development - Euro Vaccines 2025 (France)
- Vaccine Research and Development - GLOBAL VACCINE 2025 (Indonesia)
- Vaccine Research and Development - VACCINES WORLD 2025 (Italy)
- Vaccine Safety, Efficacy & Regulatory Affairs - VACCINES WORLD 2025 (Italy)
- Vaccines against Viral and Bacterial Diseases - Euro Vaccines 2025 (France)
- Vaccines and Emerging Diseases - GLOBAL VACCINE 2025 (Indonesia)
- Vaccines Business Development - Euro Vaccines 2025 (France)
- Vaccines for Older Adults - Euro Vaccines 2025 (France)
- Vaccines for Respiratory Diseases - Euro Vaccines 2025 (France)
- Vaccines for Vector-borne Diseases - Euro Vaccines 2025 (France)
- Vaccines Safety & Efficacy - Euro Vaccines 2025 (France)
- Veterinary Vaccine - VACCINES WORLD 2025 (Italy)
- Veterinary Vaccines - Euro Vaccines 2025 (France)
- Veterinary vaccines - GLOBAL VACCINE 2025 (Indonesia)